The liver in sickle cell disease - 29/11/23
Abstract |
Liver involvement in SCD patients is frequent but often misdiagnosed or underestimated, except in case of advanced liver diseases. Because of so far poorly recognized forms of chronic SCD-related vascular injury that can silently evolved towards end stages or facilitate ACLF, any persisting liver function tests abnormalities should be carefully investigated, following the above proposed algorithm. Work up and management must be considered multidisciplinary in relationship with a Hepatologist. Early SCD hepatopathy should prompt revision of SCD management to prevent further liver injury and decompensation, discussing transfusion exchanges and hydro urea when not yet initiated, and control for any cofactor of liver injury. The role of HSCT in early SCD hepatopathies also deserves evaluation. In advanced SCD hepatopathies, liver transplantation, which has been rarely performed so far, is the only therapeutic option associated with improved survival. It should definitely be discussed- either electively in case of decompensation in SCD cirrhosis or jaundice/recurrent cholangitis in cholestatic diseases, with excellent outcome, - or emergently in case of ALF or ACLF with more mitigate results.
To improve knowledge and management of SCD liver diseases, creation of national and international registries, as well as longitudinal observational cohorts are encouraged.
Le texte complet de cet article est disponible en PDF.Keywords : Sickle cell disease, Liver, SCD hepatopathy, Cholangiopathy, Sinusoidal obstruction syndrome, Porto-sinusoidal disease, Liver transplantation, Auto-immune liver diseases, Stem cells transplantation
Abbreviations : ACLF, ALF, BET, HAV, HBV, HCST, HCV, HEV, FNH, GVHD, MRI, PBC, PSC, SCD, SOS, UDCA, VOC
Plan
Vol 52 - N° 4
Article 104212- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?